Seikagaku Granted Marketing Approval for JOYCLU Joint Function Improvement Injection

Seikagaku and partner Ono Pharmaceutical announced approval from the Japan Ministry of Health, Labour and Welfare for manufacturing and marketing of JOYCLU® to treat hip and knee osteoarthritis.

The companies jointly submitted the application in 1Q20.

JOYCLU combines hyaluronic acid and the anti-inflammatory drug diclofenac,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us